AstraZeneca, Ionis’ antisense drug reduces LDL-C levels by 73% in Phase 2b trial
AZD8233 is a novel, investigational ASO therapy designed to reduce blood cholesterol levels in patients with hypercholesterolemia (elevated…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
05 Apr 22
AZD8233 is a novel, investigational ASO therapy designed to reduce blood cholesterol levels in patients with hypercholesterolemia (elevated…
10 Mar 22
The Phase 2/3 EPIC-PEDS study is designed to enrol around 140 paediatric participants, aged below 18 years of…
21 Feb 22
In the interim analysis, Dupixent showed positive results in reducing itch and hives (primary endpoints) but did not…
21 Jan 22
People who received two doses of Sputnik V showed high levels of antibodies against Omicron than those vaccinated…
19 Jan 22
The combination also showed no increase in severe liver toxicity and fewer discontinuations due to treatment-related adverse events…
13 Jan 22
In the Phase 3 study, PREVNAR 20 vaccine triggered similar responses for all 20 serotypes, either with Pfizer-BioNTech…
08 Dec 21
The vaccine showed 71% overall efficacy against all variants of SARS-COV-2, and 75.6% in people who were not…
16 Nov 21
AZD8601 is an mRNA therapeutic that encodes for vascular endothelial growth factor-A (VEGF-A), jointly developed by AstraZeneca and…
12 Nov 21
The 77.8% vaccine efficacy was based on 130 confirmed cases, where 24 cases were observed in the vaccine…
27 Oct 21
The regimen includes Merck’s nucleoside reverse transcriptase translocation inhibitor islatravir and Gilead’s potential capsid inhibitor lenacapavir